For the first time, Bavaria presented itself with its own joint booth at the LSX World Congress 2025 in London - and very prominently: The Bavarian biotech cluster was at the centre of the exhibition area together with five Bavarian companies and with the support of Bayern International and the IGZ Würzburg. The aim was to showcase the innovative strength and competitiveness of the Bavarian life science ecosystem in the UK and in particular to investors.
From 29 to 39 April 2025, the Bavarian life sciences scene presented itself at the LSX World Congress in London. The event brought together over 1,500 participants, including more than 500 investors and commercial leaders and over 250 speakers. 80% of the participants are either CxOs of up-and-coming life sciences companies, SVPs of the 30 largest pharmaceutical or T1 manufacturers or managing partners/partners of the most active investment firms in Europe/USA. The LSX World Congress thus offered an outstanding platform for targeted networking in the biotech, medtech and healthtech sectors.
In addition to over 1,000 partnering meetings, the programme also included expert panels on current topics such as ‘Artificial Intelligence vs. Actual Intelligence’, ‘European Life Science Excellence to the World Stage: Spearheading Innovation in 2025’ and ‘Navigating the Future: 2025 Investment Trends Shaping the European Biotech Sector’. A key topic was the positioning of Europe as an important location for innovation and investment in the life sciences sector - particularly in view of current geopolitical developments. Additional networking formats such as the ‘Day Zero’ programme with biotech and medtech CEO and pharma partnering forums as well as the Welcome Reception at Emirates Stadium rounded off the programme.
The strong investor presence was judged very positively: around 40 percent of the congress participants were international investors and venture capital firms. The UK ecosystem, which is one of the world's leading locations for life science investments, was particularly well represented. However, investors and global pharmaceutical companies from the USA, Scandinavia and the DACH region also took the opportunity to search specifically for innovative start-ups.With a strong presence in Milan, Bavaria is consolidating its position as an internationally recognised centre for cutting-edge biotechnological research and economic dynamism. BioM will continue to actively promote the Bavarian biotech landscape in the future and drive its growth through targeted networking and support programmes.
Bavaria's participation in the LSX World Congress was an important step towards sustainably strengthening the international visibility of Bavaria as a biotech and healthtech location - especially in the UK market. The great interest shown by investors, the high quality of the discussions held and the promising approaches for new partnerships confirm this.
Here you will find an overview of upcoming trade fair participations.